Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipogems-based combination therapy for moderate to severe knee osteoarthritis
ACTRN12615000769583Phase 2Not yet recruiting
- Sponsor
- MasterCell Stem Cell Centre
- Start
- Mar 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in knee osteoarthritis (OA) comparing Lipogems + proprietary peptides, Lipogems + platelet-rich plasma + proprietary peptides and Lipogems + Orthokine + proprietary peptides (3 arms). Primary endpoints: Knee injury and Osteoarthritis Outcome Score, Assessment of Quality of Life and 1 more. Planned start Mar 2016; status: not yet recruiting.
02
Drugs
autologous adipose-derived stem/stromal cellsplatelet-rich plasmaautologous conditioned serum
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12615000769583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000769583.